Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/20/2005US20050234068 Composition and method of decreasing renal ischemic damage
10/20/2005US20050234067 e.g. 1-(3,4-dibromo-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4.5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes
10/20/2005US20050234066 Alpha substituted carboxylic acids
10/20/2005US20050234065 Dipeptidyl peptidase-IV inhibitors
10/20/2005US20050234064 2-(4-Methoxyphenyl)-amino-),3-(aminocarbonyl-)quinoxaline; janus(JAK) kinase inhibitors;spleen tyrosine kinase(SYK) inhibitors; glycogen synthase-3(GSK-3) kinase inhibitors; immunocompetance; antiinflammatory agents; antiallergens; autoimmune diseases; antiproliferative agents; respiratory disorders
10/20/2005US20050234063 Therapeutic agent for brain hemorrhage
10/20/2005US20050234062 Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234060 Pyrrolotriazine kinase inhibitors
10/20/2005US20050234059 4-(5-Methyl-2-phenyl-pyrimidin-4-yl)-1H-pyrrole-2 carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide; Mitogen-activated protein kinase inhibitor; anticarcinogenic, antiinflammatory agent,neurodegenerative disorders, restenosis, antidiabetic, antiallergen, and cardiovascular disease
10/20/2005US20050234058 Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
10/20/2005US20050234056 Imidazoquinoline derivatives as adenosine A3 receptor ligands
10/20/2005US20050234055 Pyrazole derivative
10/20/2005US20050234054 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
10/20/2005US20050234053 9-oxo-3,4,6,9-tetrahydro-2H-[1,4]-(oxazino, thiazino, or pyrazino)[3,2-b][1,8]naphthyridine-8-carboxylic acids; fish or mammals; bacterial protein biosynthesis inhibitors
10/20/2005US20050234052 Treatment for ocular infections
10/20/2005US20050234051 5-Substituted 2-aryl-4 pyrimidinones
10/20/2005US20050234050 Ph sensitive prodrugs of 2,6-diisopropylphenol
10/20/2005US20050234049 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050234047 Respiratory syncytial virus replication inhibitors
10/20/2005US20050234046 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
10/20/2005US20050234044 Cyclic amine derivatives and methods of use
10/20/2005US20050234043 ACE inhibitor-vasopressin antagonist combinations
10/20/2005US20050234042 Organic compounds
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234039 Substituted lactams as inhibitors of Abeta protein production
10/20/2005US20050234038 Protease inhibitors
10/20/2005US20050234037 Compounds, compositions, and methods
10/20/2005US20050234036 3-(2-tetrahydrofuryl-methyl)-2-thioxanthine; neuroinflammatory disorders; pain, cancers, rheumatic arthritis, neurodegenerative diseases
10/20/2005US20050234035 New salts
10/20/2005US20050234034 One of the ring nitrogens is carbonyl-substituted, e.g., 2-(4-Chloro-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-1-[5-(2,4-dichloro-benzyl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]ethanone; inflammatory disorders (rheumatoid arthritis, multiple sclerosis)and immune disorders (transplant rejection)
10/20/2005US20050234033 1-(2-naphthylsulfonyl)-4-(5-hydroxyaminocarbonylthiazol-2-yl)piperazine;antiprolifrative agent; cell cycle arrest, cellular differentiation, apoptosis and reversal of the transformed phenotype;
10/20/2005US20050234032 Antibacterial compositions comprising metal phthalocyanine analogues
10/20/2005US20050234031 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; 2,7-bis[(2R)-azetidin-2-ylmethoxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders
10/20/2005US20050234030 Modulators of CRTH2, COX-2 and FAAH
10/20/2005US20050234029 Compounds
10/20/2005US20050234028 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol
10/20/2005US20050234027 (E)-17 alpha -fluoro-3-oxo-estra-4-en-17 beta -carbaldehyde oxime; male-type alopecia, acne and hirsutism, anticarcinogenic agents
10/20/2005US20050234026 Method and agent for inducing apoptosis/cell death in leukemia cells
10/20/2005US20050234025 Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
10/20/2005US20050234024 Materials and methods for the treatment of ulcerative colitis
10/20/2005US20050234023 Phosphorylated glyceryl ether aluminum salt
10/20/2005US20050234022 Use of 2-alkoxyphenyl-substituted imidazotriazinones
10/20/2005US20050234021 Amino phosphonate and amino bis-phosphonate derivatives
10/20/2005US20050234019 Arginine silicate inositol complex and use thereof
10/20/2005US20050234018 Drug delivery to the back of the eye
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050234016 Process for the preparation of adsorbates of valsartan and/or its solvates or hydrates
10/20/2005US20050234015 Low molecular weight heparin salt with triethanolamine useful as therapeutic-antitrombotic agent of local delivery, procedures for preparing them, process for elimination of hygroscopicity of heparin salt, pharmaceutical compositions for local use in antithrombotic therapy and uses therein
10/20/2005US20050234014 O-sulphated bacterial polysaccharides and their use
10/20/2005US20050234013 comprising a heparinoid, a local anesthetic agent and a buffering compound
10/20/2005US20050234012 Eye surgery; variations in physical properties of liquids; combinations of sodium hyaluronate and chondroitin sulfate which exhibit an improved rheological profile
10/20/2005US20050234011 Re-epithelializing pharmaceutical compositions comprising xanthan gum
10/20/2005US20050234010 Novel branched sialo-sugar molecules and antiviral agents using the same
10/20/2005US20050234009 Method of treating solid tumors and leukemias using combination therapy of vitamin D and anti-metabolic nucleoside analogs
10/20/2005US20050234008 Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
10/20/2005US20050234007 RNA interference mediating small RNA molecules
10/20/2005US20050234006 RNA interference mediating small RNA molecules
10/20/2005US20050234002 Antisense oligomers and methods for inducing immune tolerance and immunosuppression
10/20/2005US20050233999 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
10/20/2005US20050233995 Immunostimulatory nucleic acid molecules
10/20/2005US20050233992 Regeneration of endogeneous myocardial tissue by induction of neovascularization
10/20/2005US20050233991 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
10/20/2005US20050233989 Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
10/20/2005US20050233988 Novel compounds
10/20/2005US20050233987 B-cell chronic lymphocytic leukemia, splenic marginal zone lymphoma (SMZL), mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom syndrome
10/20/2005US20050233985 Rsk inhibitors and therapeutic uses thereof
10/20/2005US20050233984 Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides
10/20/2005US20050233983 Treatment of rumen acidosis with alpha-amylase inhibitors
10/20/2005US20050233982 Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
10/20/2005US20050233980 CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
10/20/2005US20050233975 Enone cancer therapeutics
10/20/2005US20050233974 Treating infectious diseases using ice inhibitors
10/20/2005US20050233970 Methods for treating long QT syndrome
10/20/2005US20050233963 Heat shock response and virus replication
10/20/2005US20050233956 Proteins involved in the regulation of energy homeostasis
10/20/2005US20050233950 Synergistic antimicrobial compositions and methods for reducing biofilm formation
10/20/2005US20050233949 Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
10/20/2005US20050233947 Combinations of chromium or vanadium with antidiabetics
10/20/2005US20050233946 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
10/20/2005US20050233944 Arginine compositions for coordinate modification of multiple cardiovascular risk factors
10/20/2005US20050233943 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
10/20/2005US20050233942 Oxygenated dibenzo-alpha-pyrone chromoproteins
10/20/2005US20050233455 Acyclic linker-containing oligonucleotides and uses thereof
10/20/2005US20050233410 Detecting cancerous and precancerous cells; obtain tissue sample, incubate wih tetrakis dyes, rince and remove unbound dye, detect fluorescence, fuorescence indicates cancerous or precancerous cells
10/20/2005US20050233402 Heparinase III HLGAG fragments and uses thereof
10/20/2005US20050233385 Using antibodies on cell surfaces
10/20/2005US20050233359 Isolated nucleic acid molecule encoding a neurotrophic growth factor
10/20/2005US20050233341 Using single nucleotide polymorphism in fucose-1-phosphate guanylyltransferase (FPGT) and cyclin dependent kinase kinesin genes as diagnostic indicators of cell proliferative disorders; antitumor agents; ribozymes and tumor treatment; RNA interference
10/20/2005US20050233323 Novel protein and dna thereof
10/20/2005US20050233317 Modulate aptamer and method of detecting target protein by using the same
10/20/2005US20050233014 Methods for affecting homeostasis and metabolism in a mammalian body
10/20/2005US20050233013 Methods for enhancing the transport of glucose for balancing blood sugar levels
10/20/2005US20050233010 mood-stabilizing lithium citrate or lithium carbonate with other psychoactive drug; antidepressant, anxiolytic agent; psychological, bipolar disorder, schizophrenia; synergistic mixture; time release; combination reduces suidical tendencies
10/20/2005US20050233008 Comprehensive pharmacologic therapy for treatment of a dysfunction
10/20/2005US20050233005 Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like
10/20/2005US20050233003 Nanosized particles of salicylic acid wrapped in an amphiphilic polymer of polyacrylic acid, polyacrylamide, polymethacrylamide and polylysine; polymer is modified with urea, nicotinamide or guanidine
10/20/2005US20050233001 Particles of megestrol, megestrol acetate, and surface stabilizer; endometriosis, dysmenorrhea, hirsutism, uterine bleeding, neoplastic diseases, appetite enhancement, contraception
10/20/2005US20050232999 Method for producing a chitosan containing salt having a function of lowering blood pressure
1 ... 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 ... 7860